Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > Simple fact

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon May 08, 2023 9:03pm

67 Views

Post# 35437644

RE:RE:RE:RE:RE:RE:Simple fact

"There's only one poster here that continues to provide Strawman arguments while promoting the status quo and the can do no wrong management team as stellar performance both in corporate developments and shareholder value."

Provide your analysis of the value CZO may have created upon the successful completion of the next set of strategic milestones. That is the measure of the value of the corporate developments to date. CZO has the cash to get to the next developments. The development path has been set in motion. It is a matter of time. Ronnie Miller has endorsed the strategic plan. The Canadian government continues to provide funding. Dr. Ask and Dr. Kolb have expressed excitement. You promoted XBC on this message board a number of times and it is now bankrupt. Who is more credible?

Using the stock price now in the worst biotech bear market in history, after revenue concentration in the first two quarters of 2022 leading to two weak quarters, and with data undisclosed on the pipeline and key catalysts next is the straw man. The current price is circumstantial and an unusual opportunity. Where will it be upon completion of the next milstones? Since becoming President and CEO the stock is also up ~500% before key milestones. CZO is on the verge of its third potential clinical asset. That is a strong record in addition to PGX and the growth in the base business.

Ciao wrote:
prophetoffactz wrote:
"provide Strawman arguments while promoting the status quo"

I'm saying that the next set of key catalysts are financed, 100% owned by CZO, and the path to them has been set in motion from Health Canada approval for the avenanthramide trial, to PGX scale-up leading to a potential deal, to the fibrosis trial which has a 'go / no go' decision this summer.

Why don't you provide a valuation of these assets upon successful completion of these defining and strategic catalysts. That is the gold.

There's only one poster here that continues to provide Strawman arguments while promoting the status quo and the can do no wrong management team as stellar performance both in corporate developments and shareholder value.